Nasdaq:US$36.56 (-0.93) | HKEX:HK$58.70 (+0.05) | AIM:£5.38 (-0.09)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China,  strive to create differentiated novel oncology and immunology treatments with global potential.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.